Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
To own Clover Health, you need to believe its technology-focused Medicare Advantage model can translate member growth into sustainable profitability, while keeping medical costs and regulatory exposure in check. The recent cybersecurity incident appears operational rather than financially material in the near term, but it reinforces data privacy as a real risk that could affect trust and, indirectly, membership and margins if such events recur.
In this context, Clover’s recent interoperability announcements, including going live on the CMS Aligned Network and TEFCA with real-time patient-directed data sharing, feel particularly relevant. These initiatives deepen Clover’s dependence on secure, connected data flows, which may enhance the value of its Clover Assistant platform but also raise the stakes around information security, a key consideration alongside upcoming earnings and the path toward GAAP profitability.
Yet even if near term financial catalysts play out as hoped, the cybersecurity and compliance risks around member data remain something investors should be aware of...
Read the full narrative on Clover Health Investments (it's free!)
Clover Health Investments’ narrative projects $4.0 billion revenue and $30.9 million earnings by 2029.
Uncover how Clover Health Investments' forecasts yield a $4.15 fair value, a 10% downside to its current price.
While the baseline view leans on tech-driven efficiency, the most pessimistic analysts were already cautious, assuming about US$3.8 billion in 2029 revenue and only US$26.3 million in earnings, and this kind of cybersecurity event could prompt you to reconsider how much weight you give to those more conservative scenarios.
Explore 4 other fair value estimates on Clover Health Investments - why the stock might be worth over 7x more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com